1
Conclusion: Attention to G6PD status is required for safe prescription of tafenoquine.
2
The effect of G6PD deficiency on risk of pneumococcal disease is undefined.
3
A commercial kit was used for the quantitative measurement of G6PD activity.
4
Quantitative diagnostic tests for G6PD deficiency are complex and require sophisticated laboratories.
5
Conclusion: Access to POC testing for G6PD deficiency in Ghana was poor.
6
Methods: Cryopreservation of erythrocytes was evaluated as a means to preserve G6PD activity.
7
The commonly used qualitative tests, do not discriminate intermediate G6PD activities.
8
Here we assessed the role of G6PD in regulating CA contractility.
9
G6PD in its active form is either a dimer or tetramer consisting identical subunits.
10
It is characterized by abnormally low levels of G6PD activity.
11
The gene for G6PD is located on the X chromosome.
12
Conclusions: A methodology for establishing a specimen panel for evaluation of G6PD tests is described.
13
Rasburicase is contraindicated in G6PD-deficient patients due to the risk of AHA and possibly methemoglobinemia.
14
The qualitative G6PD screening was performed and followed by oxidative burst analysis using flow cytometry.
15
Erythrocyte G6PD deficiency is the most common worldwide enzymopathy.
16
The G6PD activity was determined using a quantitative assay.